Screener
MBX Biosciences, Inc. MBX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Interest and other income, net | 3,748 | 2,649 |
| Net loss | $(23,517) | $(23,880) |
| Unrealized loss on marketable securities | (892) | (2) |
| Total other comprehensive loss | (892) | (2) |
| Total comprehensive loss | $(24,409) | $(23,882) |
| Net loss attributable to common stockholders | $(23,517) | $(23,880) |
| Net loss per common share, basic and diluted | $(0.50) | $(0.71) |
| Weighted average number of common shares outstanding used in computation of net loss per common share, basic and diluted | 46,576,204 | 33,412,386 |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s EPS (basic)?
- MBX Biosciences, Inc. (MBX) reported EPS (basic) of -$0.50 in Q1 2026.
- How has MBX Biosciences, Inc.'s EPS (basic) changed year-over-year?
- MBX Biosciences, Inc.'s EPS (basic) increased by 29.6% year-over-year, from -$0.71 to -$0.50.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about MBX Biosciences, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude